Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Fexuprazan and Aspirin in Healthy Subjects
NCT05304845Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fexuprazan in gastroesophageal reflux disease (GERD) (2 cohorts), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration of Aspirin up to 21 days, Steady State Maximum Plasma Concentration of DWP14012 up to 13 days and 5 more. Started Mar 2022; status: completed.
02
Drugs
fexuprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05304845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304845.